Kyle M Kampman
Overview
Explore the profile of Kyle M Kampman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
2194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cardamone N, Stewart R, Kampman K, Marcus S
Addict Sci Clin Pract
. 2025 Feb;
20(1):7.
PMID: 39905512
Background: Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains...
2.
Cardamone N, Stewart R, Kampman K, Marcus S
Res Sq
. 2024 May;
PMID: 38746408
Background: Medications for opioid use disorder (MOUD) are among the best tools we have to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD)...
3.
Dugosh K, Lent M, Burkley S, Millard C, McKay J, Kampman K
J Addict Med
. 2023 Oct;
17(5):612-614.
PMID: 37788620
Objectives: Medications for opioid use disorder (MOUDs) like buprenorphine are a first-line treatment for individuals who have opioid use disorder (OUD); however, these medications are not designed to impact the...
4.
Shi Z, Li X, Kampman K, Childress A, Wiers C, Langleben D
J Clin Psychiatry
. 2023 Apr;
84(3).
PMID: 37074295
No abstract available.
5.
Kiluk B, Kleykamp B, Comer S, Griffiths R, Huhn A, Johnson M, et al.
JAMA Psychiatry
. 2022 Nov;
80(1):84-92.
PMID: 36449315
Importance: Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor...
6.
Stewart R, Cardamone N, Mandell D, Kwon N, Kampman K, Knudsen H, et al.
J Subst Abuse Treat
. 2022 Oct;
144:108900.
PMID: 36265323
Introduction: Despite their well-established effectiveness, medications for opioid use disorder (MOUD) are widely underutilized across the United States. In the context of a large publicly funded behavioral health system, we...
7.
Kember R, Vickers-Smith R, Xu H, Toikumo S, Niarchou M, Zhou H, et al.
Nat Neurosci
. 2022 Sep;
25(10):1279-1287.
PMID: 36171425
Despite an estimated heritability of ~50%, genome-wide association studies of opioid use disorder (OUD) have revealed few genome-wide significant loci. We conducted a cross-ancestry meta-analysis of OUD in the Million...
8.
Kuijper F, Mahajan U, Ku S, Barbosa D, Alessi S, Stein S, et al.
Neuromodulation
. 2022 Feb;
25(2):253-262.
PMID: 35125144
Objectives: Cocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet...
9.
Crist R, Vickers-Smith R, Kember R, Rentsch C, Xu H, Edelman E, et al.
Drug Alcohol Depend
. 2021 Sep;
227:109013.
PMID: 34488071
Background: Buprenorphine, approved for treating opioid use disorder (OUD), is not equally efficacious for all patients. Candidate gene studies have shown limited success in identifying genetic moderators of buprenorphine treatment...
10.
Bentzley B, Han S, Neuner S, Humphreys K, Kampman K, Halpern C
JAMA Netw Open
. 2021 May;
4(5):e218049.
PMID: 33961037
Importance: In the US and the United Kingdom, cocaine use is the second leading cause of illicit drug overdose death. Psychosocial treatments for cocaine use disorder are limited, and no...